The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
A pharmacokinetic analysis program (multi) for microcomputer.
YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T., & UNO, T. (1981) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.4.879 · Cited by 2,450
The superfamily of organic anion transporting polypeptides
Hagenbuch, B., & Meier, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00633-8 · Cited by 861
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Self-citationImpact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Self-citationContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Self-citationPharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Kobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Self-citationNeuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Annual Review of Pharmacology,
Williams, J. F. (1975) · Archives of Internal Medicine · doi:10.1001/archinte.1975.00330100136032 · Cited by 386
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Self-citationEVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336
Self-citationGemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Sasaki, M., Suzuki, H., Ito, K., Abe, T., & Sugiyama, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109081200 · Cited by 228
Self-citationTamai, I., Nozawa, T., Koshida, M., Nezu, J.-I., Sai, Y., & Tsuji, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1013077609227 · Cited by 211
Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle: Are all Statins the Same?
Evans, M., & Rees, A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00004 · Cited by 210
Sugiyama, D., Kusuhara, H., Shitara, Y., Abe, T., Meier, P. J., Sekine, T., Endou, H., Suzuki, H., & Sugiyama, Y. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29383-6 · Cited by 199
Self-citationMatsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085589 · Cited by 190
Self-citationShimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004622 · Cited by 183
Self-citationBindingDB (2013) · PubMed · doi:10.7270/q2xw4m2t · Cited by 178
Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Self-citationOlbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Campbell, S. D., de Morais, S. M., & Xu, J. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.08.008 · Cited by 144
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136 · cited 1×
“Pitavastatin is a highly potent inhibitor of HMG-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis (Aoki et al., 1997; Kajinami et al., 2003).”
BackgroundIchimaru, N., Takahara, S., Kokado, Y., Wang, J. D., Hatori, M., Kameoka, H., Inoue, T., & Okuyama, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00438-5 · Cited by 130
Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Sato, F., KIMATA, H., et al. (1997) · PubMed · Cited by 104
Clark, W. G., Brater, D. C., & Johnson, A. R. (1992) · Medical Entomology and Zoology · Cited by 102
KIMATA, H., Fujino, H., Koide, T., Yamada, Y. M. A., Tsunenari, Y., & Yanagawa, Y. (1998) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.13.484 · Cited by 51
Mathew, P. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.11.125 · Cited by 32
Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs.
Kojima, J., OHSHIMA, T., Yoneda, M., & Sawada, H. (2001) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.16.497 · Cited by 14
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationImpact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Roth, M., Obaidat, A., & Hagenbuch, B. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01724.x · Cited by 767
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Metadata
- Authors
- Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 34
- Issue
- 7
- Pages
- 1229-1236
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2028444358
- Cited by
- 302
- References
- 36
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.